Table 1 Patient and transplant characteristics
Characteristics | Plerixafor group | Control group | p value |
|---|---|---|---|
n = 30 | n = 95 | ||
Age (years), median (range) | 47 (20–61) | 50 (19–67) | 0.06 |
Sex | 0.89 | ||
 Male | 15 (50 %) | 51 (54 %) |  |
 Female | 15 (50 %) | 44 (46 %) |  |
Diagnoses | 0.13 | ||
 ALL | 11 (36 %) | 10 (11 %) |  |
 AML/MDS | 15 (50 %) | 60 (63 %) | |
 Chronic lymphocytic leukemia |  | 3 (3 %) | |
 Chronic myelogenous leukemia | 2 (6 %) | 5 (5 %) | |
 Hodgkin’s lymphoma |  | 1 (1 %) | |
 Multiple myeloma |  | 1 (7 %) | |
 Mycosis fungoides |  | 1 (1 %) | |
 Myelofibrosis | 1 (3 %) | 3 (3 %) | |
 Myeloproliferative disorder |  | 3 (3 %) | |
 Non-Hodgkin’s lymphoma | 1 (3 %) | 7 (7 %) | |
Conditioning regimen | 0.23 | ||
 TBI + cyclophosphamide | 12 (40 %) | 20 (21 %) |  |
 TBI + fludarabine |  | 1 (1 %) | |
 TBI + melphalan |  | 1 (1 %) | |
 TBI + VP-16 | 1 (3 %) | 7 (7 %) | |
 Busulfan + cyclophosphamide | 13 (43 %) | 34 (35 %) | |
 Busulfan + fludarabine | 4 (13 %) | 31 (32 %) | |
 Fludarabine + melphalan |  | 1 (1 %) | |
GVHD prophylaxis | |||
 Tacrolimus + methotrexate | 30 (100 %) | 95 (100 %) |  |
Donor type | 0.85 | ||
 Matched related | 11 (37 %) | 31 (33 %) |  |
 Matched unrelated | 19 (63 %) | 64 (67 %) |  |
Graft source | 0.09 | ||
 Bone marrow | 2 (6 %) | 0 |  |
 Peripheral blood stem cells | 28 (94 %) | 95 (100 %) |  |
Total CD34+ cell dose (×10^6 cells/kg) median (range) | 6.01 (1.25–8.5) | 6.93 (1.49–10.3) | 0.09 |